AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03913754 — intervention group
Intervention type: OTHER
Intervention: Psycho-social consequences of lupus erythematosus
Description: It will be necessary to take into account the psychosocial experience of the disease \[47\] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease). The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
Study NCT01737775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragmatic amplitude measurement
Description: Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
Study NCT01902108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
Study NCT01902108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
Study NCT02801175 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary vein isolation
Study NCT00909272 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar medial branch block
Description: The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
Study NCT00909272 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound landmarks
Description: The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
Study NCT02790229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-gravity treadmill (alter G®)
Description: Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
Study NCT02790229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standardized physiotherapy
Description: Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
Study NCT03322800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
Study NCT03563144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Albumin-binding prodrug of doxorubicin HCl
Study NCT03563144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03563144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study NCT03563144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
Study NCT03563144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine
Study NCT03563144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
Study NCT03563144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
Study NCT03731013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Description: Participants randomized in the Mediterranean diet group without physical activity will be instructed and supported towards adhering to principles of the Mediterranean diet, without changes in physical activity habits.
Study NCT03731013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Description: Participants randomized in the group physical activity without Mediterranean diet will participate in a structured, supervised PA program to achieve 150 min of moderate PA per week, without changes in dietary habits.
Study NCT03731013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet and physical activity
Description: The combination group (MedDiet + PA) will receive the combination of both interventions.
Study NCT00275613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
Study NCT03322800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study NCT00896259 — intervention group
Intervention type: OTHER
Intervention: home based exercise and education program
Description: Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
Study NCT03322800 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
Study NCT01155141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
Study NCT02813460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
Study NCT00847028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose 10%
Description: 2 minutes prior to the venipuncture, a 10% glucose concentration was administered orally
Study NCT00847028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% glucose
Description: 2 minutes prior to the venipuncture, a 20% glucose concentration was administered orally
Study NCT00847028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose 30%
Description: 2 minutes prior to the venipuncture, a 30% glucose concentration was administered orally
Study NCT00847028 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile water
Description: 2 minutes prior to the venipuncture, sterile water was administered orally
Study NCT02948894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Description: an oral appliance (a dental device) for obstructive sleep apnea
Study NCT02948894 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mandibular advancement device
Description: an oral appliance (a dental device) for obstructive sleep apnea
Study NCT03200821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Description: 250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
Study NCT03200821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 µg/m\^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
Study NCT03572296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
Study NCT03572296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyphenol and fibre
Description: Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
Study NCT03572296 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibre
Description: Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
Study NCT03704688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 0.5 mg
Description: 0.5mg PO q daily
Study NCT03704688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 1 MG
Description: 1.0 mg PO q daily
Study NCT03704688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 MG
Description: 1.5mg PO q daily
Study NCT03704688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg
Description: 2 mg PO q daily
Study NCT03704688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 MG
Description: 15mg PO q daily
Study NCT03704688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 MG
Description: 30mg PO q daily
Study NCT02826096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Description: The brief version of biofeedback therapy is conducted by psychologists following the structure way. Biofeedback therapy is six session treatment once a week.
Study NCT04335864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic salpingectomy
Description: 39 patients with hydrosalpinx will have laparoscopic salpingectomy
Study NCT04335864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hystroscopic proximal tubal occlusion
Description: 39 patients with hydrosalpinx will have hysteroscopic proximal tubal occlusion
Study NCT04419168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cCBT
Description: A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both cCBT.
Study NCT04419168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: m-Education
Description: A digital, internet-delivered, evidence-based chatbot programmed to deliver content for both m-Education.
Study NCT02712853 — intervention group
Intervention type: OTHER
Intervention: Saliva collection
Description: Collection of saliva via swab for miRNA processing
Study NCT02712853 — intervention group
Intervention type: OTHER
Intervention: Vineland Adaptive Behavior Scale-II Assessment
Study NCT01426126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol PM
Description: Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
Study NCT03268863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Google Cardboard virtual reality headset
Study NCT03268863 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cold Pressor
Description: A cold ice water bath for use in pain/discomfort simulation
Study NCT03268863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor
Description: A cold ice water bath for use in pain/discomfort simulation
Study NCT01768273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT01768273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Study NCT02911116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Subcutaneous Injection
Study NCT02911116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Intravenous Infusion
Study NCT02859012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)
Study NCT02859012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: this group is observational ones.
Study NCT01482221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765 iv
Description: 50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
Study NCT01482221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765 iv
Description: 100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
Study NCT01482221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9 sodium chloride \[normal saline\] solution for injection by iv infusion
Study NCT01549509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP Vaccine
Description: All participants will receive one injection in their upper arm of 1 x 10\^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.
Study NCT02115152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT02115152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT02115152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT02115152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT02115152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Study NCT02115152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT01159847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: sitagliptin tablet,100 mg p.o. qd,2 year
Study NCT01159847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study NCT01159847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study NCT03436719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antibiotic
Description: Metronidazole - 500 mg and Erythromycin - 500 mg per os \*3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery
Study NCT03436719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous antibiotic
Description: Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
Study NCT03436719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotic
Description: Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
Study NCT03436719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Bowel Preparation
Description: Beginning of MBP at 4 p.m. in a day before surgery
Study NCT03436719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechanical Bowel Preparation
Description: Beginning of MBP at 4 p.m. in a day before surgery
Study NCT02768155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic Fluid 4.0ml dose
Description: Injection of Amniotic Fluid
Study NCT02768155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic Fluid 2.0ml dose
Description: Injection of Amniotic Fluid
Study NCT02768155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Normal Saline
Study NCT02813460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
Study NCT03025412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
Study NCT03025412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy and exercise
Description: Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
Study NCT03025412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physiotherapy and exercise
Description: Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
Study NCT02010203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-410
Description: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
Study NCT02010203 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection containing sterile solution but no cells
Study NCT02010203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Vaccine derived from a live bacterium
Study NCT02010203 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: BCG
Description: Vaccine derived from a live bacterium
Study NCT01202422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 165 mg
Description: Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.
Study NCT01202422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg
Description: 330 mg controlled release tablet administered once daily for four days.
Study NCT01202422 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 150 mg
Description: 150 mg immediate release capsules administered every 12 hours for four days
Study NCT03382925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical interlaminar with lidocaine
Description: Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.